Skip to main content

VieCure, TD2 Enter Partnership to Improve Access to Precision Oncology Trials

NEW YORK – Contract research organization TD2 and artificial intelligence informatics company VieCure on Thursday announced a collaboration to match patients treated in the community setting with precision oncology clinical trials.

Through the partnership, TD2 will have access to de-identified real-time patient data, which it will use to improve patient selection for clinical trials, while participating community oncology practices will have access to industry-sponsored trials, as well as genomic and proteomic patient data that can inform treatment strategies through the VieCure platform. According to TD2 and VieCure, the partnership will improve community oncology practices' access to next-generation sequencing, as well as to information on the latest clinical guidelines and clinical trials that may benefit patients.

"Our artificial intelligence engine supports clinicians by presenting options that may have otherwise gone unnoticed, further emphasizing the need for clinical decision support tools at the point of care to help manage the precision oncology revolution," VieCure CSO Fred Ashbury said in a statement.

Earlier this year, VieCure inked a partnership with health intelligence company Sema4 to help streamline patient access to precision oncology trials.